Filing Flows › BioXcel Therapeutics (BTAIQ) › Q4 2024
BioXcel Therapeutics (BTAIQ) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
BioXcel Therapeutics (BTAIQ) reported revenue of $366K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +71% from the quarter before.
BioXcel Therapeutics, Q4 2024: revenue $366K (-3% year over year), net loss $10.9M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $366K | +71% | -3% |
| Operating profit | −$10.5M | — | — |
| Net earnings | −$10.9M | — | — |
| Operating cash flow | −$14.8M | — | — |
What changed
Revenue was $366K in Q4 2024, down 3% year over year and up 71% from the previous quarter.
Operating costs exceeded revenue by $10.5M, an operating margin of -2866.9%. Total costs fell 46% while revenue fell 3%. The fastest-growing cost line was Cost of revenue (+17%). The quarter ended with a net loss of $10.9M, narrower than the previous quarter's $13.7M loss.
Operating cash flow was −$14.8M. Non-cash charges added back $77K of depreciation. Working capital and other items used $4.0M.
Questions
What was BioXcel Therapeutics' revenue in the fourth quarter 2024?
BioXcel Therapeutics (BTAIQ) reported revenue of $366K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +71% from the quarter before.